ABSTRACT Background: Vitamin D has been added to calcium-fortified orange juice. It is unknown whether vitamin D is as bioavailable from orange juice as it is from supplements. 
INTRODUCTION
Vitamin D (D 2 , D 3 , or both) deficiency is an international health concern (1-10) that has been associated with rickets, osteomalacia, muscle weakness, osteoporosis (11) (12) (13) (14) (15) , and an increased risk of wheezing diseases, autoimmune diseases (eg, type 1 diabetes, multiple sclerosis, rheumatoid arthritis, and Crohns disease), and cancer, such as of the prostate, breast, and colon (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) .
The major source of vitamin D is exposure to sunlight (31, 32) . A secondary yet limited source of vitamin D is through the diet (33) . Oily fish such as salmon, cod liver oil and sun-dried mushrooms are the only natural food sources of vitamin D (33, 34) .
In the 1930s, fortification of dairy products with vitamin D eradicated rickets (35) . Whereas milk is a commonly fortified food source of vitamin D, many children and adults have lactose maldigestion and avoid drinking milk (35) (36) (37) . According to the US Department of Agriculture, 49% of Americans older than 2 y drink more than one glass (236.6 mL; 8 fluid oz) of juice every day. Tangpricha et al (38) reported that orange juice fortified with 1000 IU vitamin D 3 /236.6 mL increased the serum 25-hydroxyvitamin D [25(OH)D] concentrations of adults by .150% over 12 wk, which indicated that the fortification of orange juice with vitamin D 3 is an effective way to increase vitamin D intake in adults.
Bread has been fortified with vitamin D since the 1930s (1) . It was observed that fortifying wheat and rye bread with 400 IU vitamin D 3 /100 g per serving resulted in a significant increase in serum 25(OH)D concentrations but no significant change in parathyroid hormone (PTH) concentrations after 3 wk compared with a control group (39) . However fortification of bread with 5000 IU vitamin D 3 /serving for 1 y not only increased serum 25(OH)D concentrations but also caused significant reductions in the PTH concentrations (40) . A 3-wk bioavailability study showed comparable elevations in blood 25(OH)D concentrations between subjects who ingested wild mushrooms and those who ingested 400 IU vitamin D 2 (41 
SUBJECTS AND METHODS

Subjects
A total of 105 subjects aged 18-79 y were enrolled in a doubleblind study that began on 14 February 2007 ( Table 1) . The subjects were randomly assigned into 1 of 5 groups by using a computer-generated randomization code. Potential subjects were excluded if they had a history of intestinal malabsorption, a severe medical illness, allergies, or an intolerance or dislike of orange juice or were taking a supplement containing .400 IU vitamin D/d. The subjects signed a consent form approved by the Institutional Review Board at Boston University Medical Center.
Methods
All of the vitamin D and placebo capsules were manufactured by Tishcon Corp (Salisbury, MD) and contained lactose (98.75%), magnesium stearate (1.0%), and silicon dioxide (1.25%). All of the calcium-fortified orange juices were prepared by Coca-Cola North America (Apoka, FL).
Cold water-soluble vitamin D (1000 IU) was added to every 236.6 mL calcium-fortified orange juice (39) . The vitamin D was miscible, although labels instructing subjects to shake well before each use were placed on each orange juice container to ensure that the vitamin D was evenly distributed.
Stability of vitamin D in orange juice and capsules
HPLC was used to determine the amount and stability of vitamin D 2 and vitamin D 3 i n the orange juice and capsules. The orange juice and capsules were found to contain either no vitamin D (placebo) or vitamin D within 10% of their specified concentrations.
Design
The study began in mid-February 2007. The subjects were randomly assigned into 1 of 5 groups: 1) placebo capsule + orange juice without vitamin D (placebo orange juice), 2) placebo capsule + orange juice containing 1000 IU vitamin D 3 / 236.6 mL, 3) placebo capsule + orange juice containing 1000 IU vitamin D 2 /236.6 mL, 4) 1000 IU vitamin D 3 capsule + placebo orange juice, or 5) 1000 IU vitamin D 2 capsule + placebo orange juice. All orange juice contained 350 mg Ca/236.6 mL. Subjects consumed one capsule and one 236.6-mL glass of orange juice daily. The subjects were instructed to drink the orange juice in the morning and to ingest the capsule at night. Blood was collected once weekly for a total of 11 wk. Calcium, albumin, parathyroid hormone (PTH), 25(OH)D 2 , and 25(OH)D 3 were measured ( Table 2) .
Analytic methods
Serum 25(OH)D was ascertained by liquid chromatography tandem mass spectroscopy at Quest Diagnostic Laboratory (San Juan Capistrano, CA) as reported previously (5) . The assay has an intraassay CV of 9% and an interassay CV of 12%. Serum PTH was assessed by using an Immutopics International PTH (1-84) enzyme-linked immunosorbent assay (San Clemente, CA). The assay has an intraassay CV of from 2.2% to 2.3% and an interassay CV of from 5.6% to 8.6%.
Statistical analyses
Statistical calculations were performed by using SAS version 9.1 (SAS Institute, Cary, NC). Mean differences and 95% CIs for calcium, albumin, 25(OH)D, and PTH from baseline to week 11 were calculated for all subjects ( Table 2 ). The mean (6 SD) areas under the curve (AUCs) for serum 25(OH)D 2 , 25(OH)D 3 , 25(OH)D total , PTH, calcium, and albumin concentrations from baseline to week 11 were calculated for each treatment group. One-factor analysis of variance was used to detect overall significant differences in AUCs between treatment groups. To detect significant differences in AUCs between specific treatment groups, Tukey's honestly significant differences test was used. Tukey's honestly significant differences test was used regardless of the outcome of the analysis of variance. All significant differences were measured at the P = 0.05 level.
RESULTS
Of the 105 subjects who started the study, 86 subjects completed the study (18 No significant difference (P . 0.05) in the AUC for serum 25(OH)D 2 was observed between the subjects who received vitamin D 2 in orange juice (127.3 6 57.9 ngÁ wk/mL) and the subjects who received vitamin D 2 in capsules (118.0 6 38.4 ng Á wk/mL) ( Figure 2B ). However, the AUC for serum 25(OH)D 2 was significantly different (P , 0.0001) between the subjects who received vitamin D 2 in orange juice and those who received placebo in orange juice (11.4 6 28.7 ng Á wk/mL) ( Figure 2B ). No significant overall difference in PTH was observed between the groups (P = 0.82).
DISCUSSION
The bioavailability of vitamin D in orange juice and capsules was determined by analyzing the AUCs of serum 25(OH)D 2 and serum 25(OH)D 3 . It was determined that the bioavailability of Serum PTH concentrations decreased in subjects who consumed orange juice fortified with vitamin D and calcium, vitamin D 3 capsules, or placebo; however, the results were not statistically significant. Overall, there was no statistically significant difference in serum PTH concentrations between any of the groups (P = 0.82).
Two studies have suggested that vitamin D 3 is more effective than vitamin D 2 at maintaining serum 25(OH)D concentrations (42, 43) . The results of our study indicate that consumption of 1000 IU vitamin D 2 or vitamin D 3 in orange juice was equally as effective as 1000 IU vitamin D 2 or D 3 in capsule form in raising and maintaining circulating concentrations of total 25(OH)D (Figure 1, A and B) . The results are consistent with our previous observation that the consumption of 1000 IU vitamin D 2 daily in capsule form was equally as effective as consuming a 1000-IU capsule of vitamin D 3 in raising serum 25(OH)D 2 and 25(OH) D 3 (44) . Quest Diagnostics/Nichols Institute is a clinical laboratory that specializes in liquid chromatography tandem mass spectroscopy and performed the 25 (OH)D assays for this study. We thank Jeff Mathieu for measuring the serum concentrations of PTH in all of the specimens and the staff at the Mattapan Community Health Center for their help in recruiting the study subjects.
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